Finance is moving toward 24/7 markets. Money still often moves on old banking clocks.
Our latest looks at why BMO, CME Group, and Google Cloud are part of a bigger shift: the real fintech race is no longer just about stablecoins — it’s about regulated, programmable dollars institutions can actually use at market speed.
Read: https://fintech.industryexaminer.com/tokenized-bank-money-fintech-race/
#Fintech #BMO #CMEGroup #GoogleCloud #Tokenization #Banking #Payments #TechNews #FintechNews
AI’s next bottleneck may not be chips.
It may be electricity.
Our latest feature argues the AI race is becoming an infrastructure race — and that batteries, grid flexibility, substations, and power delivery could matter more than many expected.
Read:
https://climatetech.industryexaminer.com/ai-power-bottleneck-climate-tech-batteries-grid/
#ClimateTech #AI #EnergyStorage #DataCenters #Grid #TechNews
Merck’s $6.7B Terns buy is less about leukemia than life after Keytruda.
When one drug drives nearly half of revenue, M&A becomes a way to buy time before the patent cliff.
Read:
https://biotech.industryexaminer.com/merck-terns-deal-keytruda-patent-cliff-biotech-m-and-a/
#Biotech #Pharma #Merck #Oncology #PatentCliff #BiotechM&A #TechNews #BioTechne
The old ranch was built with wire. The next one may be drawn on a smartphone.
Halter’s $220M raise is a fascinating test of whether virtual fencing is becoming real infrastructure, not just an agtech demo.
https://agtech.industryexaminer.com/halter-220m-virtual-fencing-software-defined-ranching/
#AgTech #VirtualFencing #LivestockTech #Ranching #TechNews #IndustryExaminer
Biotech AI is becoming an infrastructure race.
Roche’s latest Nvidia build points to a bigger shift: the next pharma moat may come from compute, data and workflows at scale.
https://biotech.industryexaminer.com/biotech-ai-infrastructure-race-roche-nvidia/
#Biotech #AI #Pharma #Roche #NVIDIA #TechNews #IndustryExaminer
Anduril’s ExoAnalytic deal is about more than telescopes. It’s a bet that the next edge in missile defense will come from owning the orbital picture: tracking, data, software, and command.
Read our latest:
https://spacetech.industryexaminer.com/anduril-exoanalytic-acquisition-golden-dome-space-missile-defense/
#SpaceTech #DefenseTech #GoldenDome #MissileDefense #TechNews #DeepSpace
London’s fintech rise is not just a ranking story. It reflects a deeper shift in what the market rewards: regulation, infrastructure, institutional depth, and resilience over hype.
Our latest feature:
https://fintech.industryexaminer.com/london-fintech-lead-new-york-san-francisco-funding-regulation/
#Fintech #London #UKFintech #VC #Payments #DigitalBanking #FintechNews #TechNews
Solar won the cost argument years ago. The harder test is reliability.
Masdar’s Abu Dhabi project pairs 5.2 GW of solar with 19 GWh of storage to target 1 GW of round-the-clock power. That could reshape how clean power is sold.
https://climatetech.industryexaminer.com/masdar-abu-dhabi-round-the-clock-solar-battery-storage/
China is no longer just a biotech market. It is increasingly a source of licensable innovation for global pharma.
Sanofi’s up-to-$1.53B rovadicitinib deal is the latest signal — and part of a much bigger shift in where drug innovation begins.
https://biotech.industryexaminer.com/sanofi-china-biotech-licensing-global-innovation/
#Biotech #Pharma #ChinaBiotech #DrugDevelopment #BiotechNews #TechNews
Biologicals want to go mainstream.
They may first have to earn it on the seed.
Our latest #AgTech feature looks at why seed treatment could become the real proving ground for crop biologicals — with Ascribe Bio, Corteva, and the wider competitive context around Syngenta and BASF. https://agtech.industryexaminer.com/biological-seed-treatment-crop-protection-breakthrough/
#CropProtection #SeedTreatment #Biologicals #Agriculture #TechNews
